NEUP
$4.61+0.21 (+4.77%)
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Recent News
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?
Key Insights Neuphoria Therapeutics' estimated fair value is US$3.34 based on 2 Stage Free Cash Flow to Equity...
BC-Most Active Stocks
td class="col-issue">New Era Energy & Digital Inc.
Neuphoria scraps social anxiety hopeful after Phase III miss
Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes that BNC210 may have hope in PTSD.
Investors Parse Earnings Reports With US Equity Futures Flat Tuesday Pre-Bell
US stock futures were little changed in Tuesday's premarket session as investors parsed pre-market e